AU2014200464A1 - Oral dosage form providing fast absorption of drug - Google Patents
Oral dosage form providing fast absorption of drug Download PDFInfo
- Publication number
- AU2014200464A1 AU2014200464A1 AU2014200464A AU2014200464A AU2014200464A1 AU 2014200464 A1 AU2014200464 A1 AU 2014200464A1 AU 2014200464 A AU2014200464 A AU 2014200464A AU 2014200464 A AU2014200464 A AU 2014200464A AU 2014200464 A1 AU2014200464 A1 AU 2014200464A1
- Authority
- AU
- Australia
- Prior art keywords
- diclofenac
- soft gelatin
- salt
- pain
- gelatin capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 239000006186 oral dosage form Substances 0.000 title claims abstract description 9
- 238000010521 absorption reaction Methods 0.000 title abstract description 19
- 229940079593 drug Drugs 0.000 title abstract description 13
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229960001259 diclofenac Drugs 0.000 claims abstract description 19
- 239000007903 gelatin capsule Substances 0.000 claims description 44
- 208000002193 Pain Diseases 0.000 claims description 27
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 claims description 27
- 229960004515 diclofenac potassium Drugs 0.000 claims description 25
- 230000036407 pain Effects 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 238000007619 statistical method Methods 0.000 claims description 4
- 238000012065 two one-sided test Methods 0.000 claims description 4
- 238000000540 analysis of variance Methods 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims 2
- 239000002775 capsule Substances 0.000 description 11
- 229960001680 ibuprofen Drugs 0.000 description 11
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 206010043255 Tendonitis Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000004678 Elbow Tendinopathy Diseases 0.000 description 2
- 201000011275 Epicondylitis Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 208000010040 Sprains and Strains Diseases 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 208000000491 Tendinopathy Diseases 0.000 description 2
- 208000002240 Tennis Elbow Diseases 0.000 description 2
- IHHXIUAEPKVVII-ZSCHJXSPSA-N [(1s)-5-amino-1-carboxypentyl]azanium;2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound OC(=O)[C@@H](N)CCCC[NH3+].CC(C)CC1=CC=C(C(C)C([O-])=O)C=C1 IHHXIUAEPKVVII-ZSCHJXSPSA-N 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 208000019258 ear infection Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000020947 enthesitis Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229940051201 quinoline yellow Drugs 0.000 description 2
- IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 2
- 235000012752 quinoline yellow Nutrition 0.000 description 2
- 239000004172 quinoline yellow Substances 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 201000004415 tendinitis Diseases 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 101150083127 brox gene Proteins 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 229940047475 cataflam Drugs 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 229960005466 diclofenac diethylammonium Drugs 0.000 description 1
- DCERVXIINVUMKU-UHFFFAOYSA-N diclofenac epolamine Chemical compound OCC[NH+]1CCCC1.[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCERVXIINVUMKU-UHFFFAOYSA-N 0.000 description 1
- 229960000942 diclofenac epolamine Drugs 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 201000010603 frozen shoulder Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- WZWGGYFEOBVNLA-UHFFFAOYSA-N sodium;dihydrate Chemical compound O.O.[Na] WZWGGYFEOBVNLA-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 210000004357 third molar Anatomy 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229940063674 voltaren Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Abstract The invention relates to a certain oral dosage form providing absorption of the drug diclofenac in an ultrafast manner.
Description
AUSTRALIA Regulation 3.2 Patents Act 1990 Complete Specification Standard Patent APPLICANT: Novartis AG Invention Title: ORAL DOSAGE FORM PROVIDING FAST ABSORPTION OF DRUG The following statement is a full description of this invention, including the best method of performing it known to me: WO 2008/141888 PCT/EP2008/054983 Oral dosage form providing fast absorption of druq The present invention relates to oral administration of the drug diclofenac which has been widely used as, inter alia, an anti-inflammatory agent or for the treatment of pain. For the treatment of pain, an obvious goal is to have a rapid onset of action for an as early a relief as possible of the patient. It is accepted that onset of action is directly related to rate of absorption. In the art, the rate of absorption is usually described by the use of the pharmacokinetic parameters "time to peak plasma concentration" (tmax) and "peak plasma concentration" (Cmax). However, these parameters are limited in their ability to assess rate of absorption and the Federal Drug Administration in the USA have introduced a new criterion to be used to assess early exposure. An early exposure measure may be indicative of the clinical onset of action. This is called the AUCmaxref which is defined as the area under the pharmacokinetic curve (AUC) until the median tmax for the reference formulation. This measure of early systemic exposure, together with peak exposure (Cmax) will better assess the rate and extent of absorption. It is further known that the fundamental processes controlling drug absorption are drug dissolution and gastrointestinal permeability. As a consequence it is also known that the physicochemical characteristics of the drug and/or the dosage form can affect the rate of absorption and therefore onset of action. For drugs which have low solubilities and dissolution rates such as ibuprofen and diclofenac - classified as so-called Class || compounds according to the "Biopharmaceutics Classification System" - it is known that the rate of absorption is limited by the dissolution rate of the drug. It is very well known in the art that for drugs with poor solubility and dissolution rates the use of a salt form of the drug acts to buffer the solution and modify the microenvironment which act to increase the solubility and dissolution rate respectively, leading to an increased absorption rate. Relevant examples from the art include pharmacokinetic studies where it was demonstrated that an ibuprofen salt - ibuprofen lysinate - is more rapidly absorbed than ibuprofen administered as the free acid.
WO 2008/141888 PCT/EP2008/054983 -2 It is also known in the art that a soft gelatin capsule containing dissolved ibuprofen has fast absorption (tmax=0.54 h), as does a tablet comprising ibuprofen lysinate (tmax=0.54 h), both being faster than a tablet comprising ibuprofen (tmax=1.3 h), in a pharmacokinetic study with the drug dosed at 400mg. It is also known in the art that for ibuprofen the sodium dihydrate salt (tmax=0.6 h) has the same fast absorption rate when compared to tablets comprising ibuprofen lysinate salt (tmax=0.7 h) and ibuprofen soft gelatin capsules comprising dissolved ibuprofen (tmax=0.7 h), all much faster than tablets comprising ibuprofen (tmax=1.4 h). Oral dosage forms comprising a salt form of diclofenac such as the potassium salt are known in the art and have fast absorption as observed in a study which showed that a tablet comprising diclofenac potassium salt had a tmax of 0.9 h. An object of the present invention was to find an oral dosage form of diclofenac with substantially faster absorption, i.e. onset of action, than the - already fast absorbed diclofenac potassium tablets (e.g. Voltaren Dolo@, Cataflam@) mentioned above. When tentatively applying the "soft gelatin capsule" technology to diclofenac, especially with a soft gelatin capsule comprising dissolved potassium diclofenac, the present inventors expected, an analogy to ibuprofen, that diclofenac salt tablets and soft gelatin capsules should have similar absorption rates. Surprisingly, however, it has been found that when applying (dissolved) diclofenac salts in soft gelatin capsules, the rate of absorption is ultrafast compared with the already fast-acting potassium salt tablets. The invention therefore relates to the use of a pharmaceutically acceptable diclofenac salt (for the manufacture of an oral medicament) in the form of a soft gelatin capsule for the ultrafast treatment of pain, wherein said pharmaceutically acceptable diclofenac salt is present in said soft gelatin capsule in solution; and wherein said ultrafast treatment of pain is defined by an AUCmaxref value (area under curve until median tmax for the reference formulation) which is statistically significantly numerically higher than for an oral dosage form tablet comprising diclofenac potassium at the same dosage [statistical method applied: two one-sided tests procedure (average bioequivalence): WO 2008/141888 PCT/EP2008/054983 -3 analysis of variance of log-transformed AUCmaxref including terms for sequence, treatment, and period as fixed effects and subject nested within sequence as a random effect]. The statistical method to be applied for assessing AUCmaxref values is the "two one-sided tests" one (average bioequivalence) described in detail in FDA/CDER Guidances for Industry: Statistical Approaches to Establishing Bioequivalence (Jan 2001); Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations (Mar 2003). In another embodiment of the invention, it relates to the use of a pharmaceutically acceptable diclofenac salt (for the manufacture of an oral medicament) in the form of a soft gelatin capsule for the ultrafast treatment of pain, wherein said pharmaceutically acceptable diclofenac salt is present in said soft gelatin capsule in solution; and wherein said ultrafast treatment of pain is defined by an AUCmaxref value (area under curve until median tmax for the reference formulation) of at least 175 ng x hour/mL - preferably at least 180 ng x hour/mL, especially at least 220 ng x hour/mL and in particular at least 250 ng x hour/mL - derived from a pharmacokinetic graph "diclofenac concentration (in the blood) versus time". For determining AUCmaxref values, the following criteria do apply: (at least) 42 volunteers, fasted condition, cross-over study, number of sampling points:17, samples taken at time pre dose, 15 min, 25 min, 35 min, 45 min, 1.0 h, 1.25 h, 1.5 h, 1.75 h, 2.0 h, 2.5 h, 3.0 h, 3.5 h, 4.0 h, 6.0 h, 8.0 h, and 10 h post-dosing. As to the doses of pharmaceutically acceptable diclofenac salt incorporated into one soft gelatin capsule, these typically are of from 5 up to 100 mg - preferably of from 10 up to 50 mg, especially of from 10 up to 30 mg and in particular of from 10 up to 25 mg. As to the dosing of the pharmaceutically acceptable diclofenac salt in the disclosed uses, the total dose (administered at the same time, i.e. simultaneously) of said diclofenac salt applied typically is of from 5 up to 100 mg - preferably of from 10 up to 50 mg, especially of from 10 up to 30 mg and in particular of from 10 up to 25 mg. Said total dose may be applied in the form of one or more - preferably one or two, especially two, in another embodiment one - soft gelatin capsule(s).
WO 2008/141888 PCT/EP2008/054983 -4 A total daily dosage above 225 mg per patient typically is not recommended. The term "pain" is intended to include all forms of pain and ache, e.g. - mild to moderate acute body pain caused by activity/overuse such as: bumps and bruises, strains and sprains, insect stings and minor cuts, sore muscle, tendonitis, tennis elbow, golfer's elbow or enthesitis - mild to moderate persistent body pain caused by degenerative conditions such as: osteoarthritis, chronic back pain, osteoporosis, frozen shoulder, ankylosing spondylitis, carpal tunnel syndrome or Paget's disease - severe body pain caused by external factors such as lumbago, fractures, post-operative pain, gout attack, cervical spondylosis, rheumatoid arthritis or polymyalgia rheumatica - mild to moderate acute other pain caused by temporary conditions such as: toothache, sore throat, acute otitis and sinusitis, period pains, migraine, sunburn, herpex simplex or dyspepsia - mild to moderate persistent other pain such as fibromyalgia, tension headache, parodontitis and gingivitis, diverticulosis, intermittent claudication, thrombophlebitis or shingles - severe other pain caused by life-threatening conditions such as: heart attack, cancer pain, childbirth, renal colic, abdominal colic, trigeminal neuralgia, sciatica or cluster headache. The diclofenac soft gelatin capsules manufactured according to present invention are particular beneficial in treating pain indications where a rapid onset of action is of particular importance, e.g. all forms of acute pain such as bumps and bruises, strains and sprains, insect stings and minor cuts, sore muscle, tendonitis, tennis elbow, golfer's elbow, enthesitis, post-operative pain, toothache, sore throat, acute otitis and sinusitis, period pains, headache, migraine, sunburn, herpes simplex or dyspepsia. A pharmaceutically acceptable salt of diclofenac is e.g. diclofenac sodium, diclofenac potassium, diclofenac diethylammonium or diclofenac epolamine. In particular preferred is diclofenac potassium. A method for manufacturing soft gelatin capsules had been found in the 1930's already, by which a capsule can be produced and filled in a single operation. Thus, the term "soft gelatin capsule" is generally acknowledged and well understood in the field of pharmaceutical technology. Essentially, a soft gelatin capsule comprises a shell of gelatin which is filled with WO 2008/141888 PCT/EP2008/054983 -5 and encloses a liquid. Said liquid, according to the present invention, is preferably a solution (but may also be a suspension) of a pharmaceutically acceptable salt of diclofenac. The solvents used are e.g. oils, such as vegetable, animal or mineral oils, liquid hydrocarbons, volatile oils. polyethylene glycols or mixtures of polyethylene glycols with water. Preferred are mixtures of polyethylene glycols with water. The shell of soft gelatin capsule typically includes a softener, e.g. glycerol, sorbitol, or polyethylene glycols themselves. Preferred is a mixture of sorbitol and at least one sorbitane, e.g. "Polysorb 85/70/00" from Roquette Pharma (France). An example for suitable soft gelatin capsules, and some principles of their buildup, composition and manufacture are outlined in US patent 4,744,988 (Brox). Soft gelatin capsules comprising 12.5 mg and 25 mg of diclofenac potassium have been manufactured in a manner known per se, viz. in close analogy to the "Example" disclosed in US patent 4,744,988, columns 6 and 7 - which means using the same components as disclosed there but replacing diazepam with diclofenac potassium as active substance. In even more detail, said two compositions are as follows. Example 1: Composition of 12.5 mg Diclofenac potassium soft gelatin capsule Composition of the capsule fill contents: Name of ingredients Quantities (mg / capsule) Drug substance Diclofenac potassium 12.50 Other ingredients Macrogol 600 (= Polyethylene glycol 600) 100.00 Glycerol 85% 6.25 Purified water 6.25 Composition of the capsule shell: Name of ingredients Quantities ( mg / capsule) Gelatin 51.34 Glycerol 85% 14.93 Sorbitol liquid, partially dehydrogenated 10.86 (e.g. Polysorb 85/70/00) Quinoline yellow 70% (= El 04) 0.0060 WO 2008/141888 PCT/EP2008/054983 -6 Example 2: Composition of 25.0 mg Diclofenac potassium soft gelatin capsule Composition of the capsule fill contents: Name of ingredients Quantities (mg / capsule) Druq substance Diclofenac potassium 25.0 Other ingredients Macrogol 600 (= Polyethylene glycol 600) 200.00 Glycerol 85% 12.50 Purified water 12.50 Composition of the capsule shell: Name of ingredients Quantities (mg / capsule) Gelatin 89.85 Glycerol 85% 26.12 Sorbitol liquid, partially dehydrogenated 19.00 (e.g. Polysorb 85/70/00) Quinoline yellow 70% (= El 04) 0.011 The beneficial properties due to oral administration of diclofenac soft gelatin capsules can be seen e.g. from the following tests: (1) Comparative bioavailability study: Comparison of two 12.5 mg diclofenac potassium tablets with two 12.5 mg diclofenac potassium soft gelatin capsules The following products were compared in a two way cross over single dose pharmacokinetic study using 42 fasted healthy human volunteers: Test formula A: soft gelatin capsules from example 1 Test formula B: commercially available swallow tablets containing diclofenac potassium 12.5mg WO 2008/141888 PCT/EP2008/054983 -7 Each volunteer swallowed two samples of one of the formulations equivalent to 25mg of diclofenac potassium, followed by 240 mL of water on two separate occasions at least 14 days apart. Blood samples were taken pre-dose and at 15 min, 25 min, 35 min, 45 min, 1.0 h, 1.25 h, 1.5 h, 1.75 h, 2.0 h, 2.5 h, 3.0 h, 3.5 h, 4.0 h, 6.0 h, 8.0 h, and 10 hours post dose. Serum diclofenac potassium levels were determined by a fully validated LC/MS-MS method and diclofenac potassium plasma levels vs time plots were plotted for each volunteer. The mean AUCtmaxref for formulation A was 294 ng x hour/mL vs 158 ng x hour/mL for formulation B. Mean plasma concentration of diclofenac (ng/mL) Time Soft gelatin Tablet capsule Pre-dose 0.0 0.0 15 min 385 261 25 min 915 439 35 min 764 384 45 min 477 321 1 h 256 226 1.25 h 177 179 1.5 h 134 159 1.75 h 103 137 2 h 74 108 2.5 h 52 97 3 h 38 93 3.5 h 27 64 4h 21 41 6 h 8 10 8h 4 4 10 h Not estimable 2 (2) Comparative bioavailability study: Comparison of two 12.5 mg diclofenac potassium tablets with one 25 mg diclofenac potassium soft gelatin capsule WO 2008/141888 PCT/EP2008/054983 -8 The 25mg Diclofenac potassium soft gelatin capsule was tested in a pharmacokinetic study using a similar design as detailed under (1) for the 12.5mg Diclofenac potassium soft gelatin capsule, except that the soft gelatin capsule was administered as one 25mg dosage form instead of two 12.5mg ones. The ultrafast absorption rate for the 25mg soft gelatin capsule was observed, when compared to two 12.5mg tablets. (3) Clinical study in 3L molar extraction: Double-blind, double-dummy, placebo-controlled, parallel-group, randomized trial of diclofenac potassium soft gelatin capsule (12.5 mg) vs paracetamol (500 mg) tablets and placebo in patients with moderate or severe pain within 8 hours of extraction of impacted third molars. All are treated with an initial dose of 2 soft gelatin capsules or 2X 500 mg of paracetamol tablets or placebo followed by 1 or 2 capsules or tablets, as needed, every 4 to 6 hours, up to a maximum of 6 of each type. Efficacy in control of acute pain is determined at baseline, and then at 20 minutes, 40 minutes, 1, 2, 3, 4, 5, and 6 hours after dosing. Significantly higher levels of analgesia are observed in the soft gelatin capsule group at 20 minutes, 40 minutes and 1 hour after the initial dose, compared to paracetamol group.
Claims (13)
1. Use of a pharmaceutically acceptable diclofenac salt for the manufacture of an oral medicament in the form of a soft gelatin capsule for the ultrafast treatment of pain, wherein said pharmaceutically acceptable diclofenac salt is present in said soft gelatin capsule in solution; and wherein said ultrafast treatment of pain is defined by an AUCmaxref value (area under curve until median tmax for the reference formulation) which is statistically significantly numerically higher than for an oral dosage form tablet comprising diclofenac potassium at the same dosage [statistical method applied: two one-sided tests procedure (average bioequivalence): analysis of variance of log-transformed AUCmaxref including terms for sequence, treatment, and period as fixed effects and subject nested within sequence as a random effect].
2. Use of a pharmaceutically acceptable diclofenac salt for the manufacture of an oral medicament in the form of a soft gelatin capsule for the ultrafast treatment of pain, wherein said pharmaceutically acceptable diclofenac salt is present in said soft gelatin capsule in solution; and wherein said ultrafast treatment of pain is defined by an AUCmaxref value (area under curve until median tmax for the reference formulation) of at least 175 ng x hour/mL derived from a pharmacokinetic graph "diclofenac concentration (in the blood) versus time".
3. Use according to claim 2, wherein said ultrafast treatment of pain is defined by an AUCmaxref value of at least 250 ng x hour/mL derived from a pharmacokinetic graph "diclofenac concentration versus time".
4. Use according to claim 1, wherein the diclofenac salt used is diclofenac potassium.
5. Use according to claim 2 or claim 3, wherein the diclofenac salt used is diclofenac potassium.
6. Use according to claim 1 or claim 4, wherein the dose of said diclofenac salt is of from 5 up to 100 mg per soft gelatin capsule. WO 2008/141888 PCT/EP2008/054983 -10
7. Use according to claim 1 or claim 4, wherein the dose of said diclofenac salt is of from 10 up to 50 mg per soft gelatin capsule.
8. Use according to anyone of claims 2, 3 or 5, wherein the dose of said diclofenac salt is of from 5 up to 25 mg.
9. Use according to anyone of claims 2, 3 or 5, wherein the dose of said diclofenac salt is of from 15 up to 25 mg.
10. A method of treating pain in mammals including humans in an ultrafast manner, which method comprises orally administering a pharmaceutically acceptable salt of diclofenac in the form of at least one soft gelatin capsule, wherein said pharmaceutically acceptable salt of diclofenac is present in said at least one soft gelatin capsule in solution; and wherein said ultrafast treatment of pain is defined by an AUCmaxref value (area under curve until median tmax for the reference formulation) which is statistically significantly numerically higher than for an oral dosage form tablet comprising diclofenac potassium at the same dosage [statistical method applied: two one-sided tests procedure (average bioequivalence): analysis of variance of log-transformed AUCmaxref including terms for sequence, treatment, and period as fixed effects and subject nested within sequence as a random effect].
11. A method of treating pain in mammals including humans in an ultrafast manner, which method comprises orally administering a pharmaceutically acceptable salt of diclofenac in the form of one or more soft gelatin capsule(s), wherein said pharmaceutically acceptable salt of diclofenac is present in said soft gelatin capsule(s) in solution; and, wherein said treatment of pain in an ultrafast manner is defined by an AUCmaxref value (area under curve until median tmax for the reference formulation) of at least 175 ng x hour/mL derived from a pharmacokinetic graph "diclofenac concentration (in the blood) versus time".
12. The method according to claim 11, wherein the dose of said diclofenac salt is of from 5 up to 25 mg and is applied by administration of one or two soft gelatin capsules at the same time. WO 2008/141888 PCT/EP2008/054983 - 11
13. The method according to claim 11, wherein the dose of said diclofenac salt is of from 15 up to 25 mg and is applied by simultaneous administration of two soft gelatin capsules.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014200464A AU2014200464A1 (en) | 2007-05-24 | 2014-01-29 | Oral dosage form providing fast absorption of drug |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07108861.1 | 2007-05-24 | ||
| AU2008253125A AU2008253125B2 (en) | 2007-05-24 | 2008-04-24 | Oral dosage form providing fast absorption of drug |
| AU2014200464A AU2014200464A1 (en) | 2007-05-24 | 2014-01-29 | Oral dosage form providing fast absorption of drug |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008253125A Division AU2008253125B2 (en) | 2007-05-24 | 2008-04-24 | Oral dosage form providing fast absorption of drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2014200464A1 true AU2014200464A1 (en) | 2014-02-13 |
Family
ID=50070760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014200464A Abandoned AU2014200464A1 (en) | 2007-05-24 | 2014-01-29 | Oral dosage form providing fast absorption of drug |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2014200464A1 (en) |
-
2014
- 2014-01-29 AU AU2014200464A patent/AU2014200464A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20170319484A1 (en) | Diclofenac formulations and methods of use | |
| WO2009069139A1 (en) | Dosage form providing an ibuprofen-containing liquid fill | |
| NO327456B1 (en) | Formulations containing paracetamol and sodium bicarbonate as well as processes for the preparation thereof | |
| RU2007101686A (en) | COMBINED COMPOSITION | |
| WO2005063219A2 (en) | Ibuprofen-containing soft gelatin capsules | |
| KR20110027711A (en) | Pharmaceutical composition of rosuvastatin calcium | |
| CN1988910A (en) | Drug Combinations Containing Platelet Aggregation Inhibitors and Fibrates | |
| AU2003235700B2 (en) | Stable salts of o-acetylsalicylic acid containing basic amino acids II | |
| GB2494439A (en) | 6-Mercaptopurine oral suspension for the treatment of acute lymphoblastic leukaemia | |
| AU2008253125B2 (en) | Oral dosage form providing fast absorption of drug | |
| CN110693820A (en) | Pregabalin oral solution and preparation method thereof | |
| AU2014200464A1 (en) | Oral dosage form providing fast absorption of drug | |
| CN117304054A (en) | Methods for enriching caffeoyl-spermidine compounds, their anti-aging properties and methods for inhibiting histone deacetylase | |
| US11013707B2 (en) | Administration of oral methyldopa | |
| WO2019098984A1 (en) | Synergistic combination of diclofenac, famotidine and a carbonate | |
| JP2009235093A (en) | Pharmaceutical composition for nasal inflammation | |
| Dhamane et al. | Development and evaluation of taste masked orodispersible tablet of ofloxacin | |
| RU2174836C1 (en) | Pharmaceutical composition eliciting analgesic effect | |
| EP2965746B1 (en) | An oral pharmaceutical composition comprising ibuprofen, ibuprofen sodium dihydrate, pseudoephedrine hydrochloride and chlorpheniramine maleate | |
| KR20040071587A (en) | Oral Pediatric Trimethobenzamide Formulations and Methods | |
| Shaikh et al. | Design and characterization of orodispersible tablets of Aceclofenac | |
| HK40051811A (en) | Diclofenac formulations and methods of use | |
| TW201309286A (en) | Pharmaceutical composition comprising ketoprofen | |
| Prema | Formulation and Evaluation of Immediate Release Tablets of a Model Anti-Migraine Drug | |
| PL195966B1 (en) | Pharmacological analgesic preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |